Altoida Celebrates Historic Day for Patients with Alzheimer’s Disease

Patients Ask: Is Parkinson's Disease Hereditary?

October 25, 2022Neelem Sheikh

If you have parents or grandparents who have been diagnosed with Parkinson’s disease, or if you yourself have the disease, you have likely wondered: Is Parkinson’s disease hereditary? Is Parkinson’s disease genetically transmitted from parent to offspring?

While just over two decades ago, Parkinson’s disease was believed to have no genetic links, researchers have now attributed approximately 10-15% of Parkinson’s cases to genetic causes.

In this article, we will discuss genes linked to Parkinson’s disease and answer common questions about Parkinson’s disease genetics.

Is Parkinson’s Disease Hereditary?

Similar to many other neurodegenerative diseases, experts currently believe Parkinson’s disease is multifactorial, meaning it is not caused by a single factor but rather develops from some combination of several factors. In the case of Parkinson’s disease, these factors are primarily genetic and environmental. 

While relatively rare, Parkinson’s disease can run in families as a result of genetic variants on specific genes being inherited or passed from parents to their children. These genetic variants contribute to Parkinson’s disease risk, onset, and progression. There are also a few ethnic groups, such as the North African Arab Berbers and Ashkenazi Jews, that more frequently carry mutations on genes linked to Parkinson’s disease, though researchers have not yet figured out why.

Genes Linked to Parkinson’s Disease

Over the past several decades, researchers have discovered quite a few variants in genes that may contribute to Parkinson’s disease. Genes associated with Parkinson’s disease include but are not limited to:

  • Alpha-synuclein (SNCA): SNCA, the gene that encodes for the alpha-synuclein protein, is the first gene identified to cause autosomal-dominant Parkinson’s disease. Researchers have identified at least 30 variants in the SNCA gene that can alter the alpha-synuclein protein. Such variants have been associated with young-onset, or early-onset, Parkinson’s disease.
  • Parkin (PRKN): PRKN, the gene that provides instructions for making a protein called parkin, is the most common genetic variant associated with young-onset Parkinson’s disease. Over 200 variants in the PRKN gene have been associated with Parkinson’s disease. 
  • Parkinson’s protein 7 (PARK7): The PARK7 gene encodes for DJ-1, a protein known to protect cells from oxidative stress. Variants in PARK7 have been linked to young-onset Parkinson’s disease.
  • Leucine-rich repeat kinase 2 (LRRK2): LRRK2, the gene that provides instructions for making a protein called dardarin, is believed to be involved in 1% of all individuals with Parkinson’s and about 5% of cases with a family history.
  • PTEN-induced kinase 1 (PINK1): The PINK1 gene encodes for a protein called PTEN-induced putative kinase 1, a protein that protects mitochondria from stress-induced dysfunction.PINK1 is the second most common genetic variant linked to young-onset Parkinson’s disease.
  • Glucocerebrosidase beta (GBA): GBA is the gene that encodes for the lysosomal enzyme, beta-glucocerebrosidase. Approximately 5-10% of individuals with Parkinson’s disease have a variant in this gene.
GeneMutationYear of DiscoveryInheritance PatternFrequency
SNCAMissense or multiplication1997DominantVery rare
PRKNMissense or loss of function1998RecessiveRare
PARK7Missense 2003RecessiveVery rare
PINK1Missense or loss of function2004RecessiveRare
GBAMissense or loss of function2009Dominant (incomplete penetrance)Common 

Is Parkinson’s Disease Hereditary: FAQs

Q: If I have a genetic mutation linked to Parkinson’s disease, will I eventually develop Parkinson’s disease?

A: Having a genetic mutation that has been linked to Parkinson’s disease does not guarantee you will develop the disease. Some mutations are associated with a greater risk of developing Parkinson’s disease than others, however, there is currently no single mutation that carries a 100% chance of developing Parkinson’s.

Q: If only 10-15% of Parkinson’s disease cases are caused by genetics, what causes the other 85-90% of cases?

A: While Parkinson’s disease can be hereditary and carrying mutations on specific genes associated with Parkinson’s disease can increase your risk of developing the disease, there are a range of other environmental and lifestyle factors at play. Risk factors for Parkinson’s disease include advancing age, male sex, and toxin exposure. Risk factors for Parkinson’s disease-related dementia include less education, hearing loss, traumatic brain injury, hypertension, alcohol consumption (>21 units/week), obesity, smoking, depression, social isolation, physical inactivity, diabetes, and air pollution.

Q: Are there genetic tests for Parkinson’s disease genes?

A: Yes, there are genetic tests available for several clinically-relevant Parkinson’s disease genes. However, many of the at-home genetic tests test for only a few genetic variants linked to Parkinson’s disease and, consequently, may be misleading for patients. Genetic tests do not take the place of a formal PD diagnosis and should always be done with the guidance of a genetic counselor. The Parkinson’s Foundation PD GENEration study performs in-person and at-home genetic testing for seven Parkinson’s disease-related genes (GBA, LRRK2, PRKN, PINK1, and VPS35) and genetic counseling at no cost for people with Parkinson’s disease.

While Parkinson’s disease can be hereditary, the majority of cases are not. Even if someone tests positive for a Parkinson’s disease-related genetic variant, it does not necessarily mean they will go on to develop Parkinson’s disease but rather are at an increased risk of developing Parkinson’s disease

Pioneering Precision Neurology To Enable Early Parkinson’s Disease Diagnosis

At Altoida, we are building the world’s-first Precision Neurology platform and app-based medical device—backed by 11 years of clinical validation—to accelerate and improve drug development, neurological disease research, and patient care.

By completing a 10-minute series of augmented reality and motor activities designed to simulate complex Activities of Daily Living on a smartphone or tablet, Altoida’s device extracts and provides robust measurements of neurocognitive function across 13 neurocognitive domains. Our device measures and analyzes nearly 800 multimodal cognitive and functional digital biomarkers. Through the collection of highly granular data from integrated smartphone or tablet sensors, Altoida’s device produces comprehensive neurocognitive domain scores. 

This method, along with our innovative artificial intelligence, will pioneer fully digital predictive neurological disease diagnosis. In 2021, our device received the Breakthrough Device designation by the FDA. Altoida's platform has demonstrated the ability to predict conversion from Mild Cognitive Impairment to Alzheimer's disease with a high degree of accuracy.

Currently, we are working to enable early and accurate diagnosis of Parkinson’s disease through AI-powered precision diagnosis. Our technology will be utilized to monitor disease progression as well as to measure therapeutic response in Parkinson’s disease patients.

To learn more about the treatment of Alzheimer’s disease, or about using Altoida’s Precision Neurology platform to monitor therapeutic response, contact us today.

Contact Us

At Altoida, we use digital biomarkers to radically change the method of assessing brain health and cognitive diseases. After nearly two decades of research, we are developing a platform and device to measure and analyze cognitive biomarkers associated with cognitive impairment to evaluate perceptual and memory function.
Contact Us

Contact Us

80 M Street SE, Suite 100 Washington, DC 20003 USA 


Follow Us


By visiting our Website and/or using the Services in any manner, you acknowledge that you accept the practices and policies outlined in our Privacy Policy.

Our Disclaimer

@ Altoida 2022